Algorae Pharmaceuticals collaborates with Monash University for pre-clinical studies on AI-168 drug candidate

Algorae Pharmaceuticals Limited (ASX: $1AI) has partnered with Monash University to conduct pre-clinical studies on its AI-168 drug candidate for cardiovascular diseases. The studies aim to assess the drug's efficacy in various cardiovascular models and compare it to existing treatments. Results are expected over a 12-month period and will guide the next steps in the R&D program for AI-168.

Insights from Dr Kristen Bubb on the pre-clinical studies

Dr Kristen Bubb, a senior research fellow at the Victorian Heart Institute, Monash University, is leading the pre-clinical studies on AI-168. The studies will focus on understanding the drug's mechanism of action across different cardiovascular diseases. The results will play a crucial role in shaping the future of AI-168's development and potential patent applications.

Summary of Algorae Pharmaceuticals' collaboration and patent application

Algorae Pharmaceuticals has initiated pre-clinical studies with Monash University to evaluate its AI-168 drug candidate for cardiovascular diseases. The collaboration aims to assess the drug's efficacy and guide further R&D efforts. Additionally, the company has filed a provisional patent application for AI-168, marking the commencement of a new research and development project. The potential market for new drugs targeting cardiovascular diseases is substantial, driven by the increasing global demand for effective treatments. Algorae's focus on developing intellectual property assets aligns with its broader strategy, positioning the company for future growth and innovation in the pharmaceutical industry.